In scleroderma graft-versus-host disease (GVHD) models, NIC was reported to reverse the clinical symptoms of GVHD, including alopecia, vasculitis, and diarrhea [103], of which beneficial effects were associated with the inhibition of the STAT3, Wnt/β-catenin, ERK1/2, AKT, and Notch signaling pathways. This evidence concerns the gene MAPK3 and graft versus host disease.